Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 6/20 | 0.34 |
| ▸ | TCF4 | P15884 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | ADK | P55263 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26075314 | 0.88 | APP (0.43) | ESR1ESR2PSMB5APPTCF4 | |
| SCHEMBL26075896 | 0.86 | ESR1 (0.35) | ESR1ESR2TOP1 | |
| SCHEMBL26075419 | 0.84 | KDM1A (0.46) | ESR1ESR2APPTOP1KDM1A | |
| SCHEMBL26075894 | 0.84 | ESR1 (0.37) | ESR1ESR2APPTOP1 | |
| SCHEMBL26075865 | 0.84 | ACACA (0.46) | APP | |
| SCHEMBL26075891 | 0.82 | DHODH (0.44) | ESR1ESR2TOP1 | |
| SCHEMBL26075870 | 0.81 | MAPT (0.38) | ESR1ESR2APP | |
| SCHEMBL26075889 | 0.81 | ESR1 (0.38) | ESR1ESR2TOP1 | |
| SCHEMBL26075885 | 0.81 | HMOX1 (0.41) | ESR1ESR2CTNNB1 | |
| SCHEMBL26075879 | 0.81 | ESR1 (0.35) | ESR1ESR2APPTOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303710-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT | DHODH, CD38, DPYD | ESR1 4427/4885ESR2 4530/4885PSMB5 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.